Arthritis

March 10, 2019

Molecular therapy for inflammation and arthritis: Methylene blue(MB) (trade names: Urelene blue, Provayblue, Proveblue) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 10/March/2018, 1.29 pm

Molecular therapy for inflammation and arthritis: Methylene blue(MB) (trade names: Urelene blue, Provayblue, Proveblue) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 10/March/2018, 1.29 pm https://genomediscovery.org/wp-content/uploads/2019/03/Methelene-Blue-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-9-IL-9.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Methelene-Blue-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-9-IL-9.jpg March 10, 2019 March 10, 2019

Introduction: What they say A study from Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany shows that “Resolution of inflammation by…

March 6, 2019

Natural product-based therapy for inflammation and arthritis: Tanshinone IIA increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 6/March/2019, 10.29 pm

Natural product-based therapy for inflammation and arthritis: Tanshinone IIA increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 6/March/2019, 10.29 pm https://genomediscovery.org/wp-content/uploads/2019/03/Tanshinone-IIA-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9-.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Tanshinone-IIA-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9-.jpg March 6, 2019 March 6, 2019

March 3, 2019

Ribonucleic acid-based therapy for inflammation and arthritis: LncRNA HOTAIRM1-1 (HOX antisense intergenic RNA myeloid 1 variant 1) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/March/2018, 6.41 am

Ribonucleic acid-based therapy for inflammation and arthritis: LncRNA HOTAIRM1-1 (HOX antisense intergenic RNA myeloid 1 variant 1) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 3/March/2018, 6.41 am https://genomediscovery.org/wp-content/uploads/2019/03/LncRNA-HOTAIRM1-1-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9-IL9.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/LncRNA-HOTAIRM1-1-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9-IL9.jpg1_.jpg March 3, 2019 March 3, 2019

February 26, 2019

Natural product-based therapy for inflammation and arthritis: Oridonin, found in Rabdosia Rubescens, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis, via up-regulation of its target genes, 26/February/2018, 8.40 am

Natural product-based therapy for inflammation and arthritis: Oridonin, found in Rabdosia Rubescens, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis, via up-regulation of its target genes, 26/February/2018, 8.40 am https://genomediscovery.org/wp-content/uploads/2019/02/Oridanin-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-92.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Oridanin-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-92.jpg February 26, 2019 February 26, 2019

February 20, 2019

Molecular hydrogen-based therapy for arthritis: High-content hydrogen water (HHW) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.39 am

Molecular hydrogen-based therapy for arthritis: High-content hydrogen water (HHW) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.39 am https://genomediscovery.org/wp-content/uploads/2019/02/High-content-hydrogen-water-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-9.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/High-content-hydrogen-water-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin-9.jpg February 20, 2019 February 20, 2019

February 20, 2019

Repurposing the lipid-lowering drug Fenofibrate into an anti-arthritic drug: Fenofibrate (brand name:Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.23 am

Repurposing the lipid-lowering drug Fenofibrate into an anti-arthritic drug: Fenofibrate (brand name:Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix) increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis via up-regulation of its target genes, 21/February/2019, 12.23 am https://genomediscovery.org/wp-content/uploads/2019/02/Lipid-lowering-drug-Fenofibrate-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/Lipid-lowering-drug-Fenofibrate-attenuates-inflammatory-diseases-including-Rheumatoid-arthritis-through-up-regulation-of-Interleukin9.jpg February 20, 2019 February 20, 2019

Popular Post